Skip to main content
padlock icon - secure page this page is secure

Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia

Buy Article:

$59.00 + tax (Refund Policy)

Summary Objective 

Cabergoline is a highly effective medical treatment for patients with hyperprolactinaemia. There is an increased risk of valvular heart disease in patients receiving cabergoline for Parkinson’s disease. This study examined whether cabergoline treatment of hyperprolactinaemia is associated with a greater prevalence of valvulopathy. Design 

Cross-sectional, two-dimensional echocardiographic study performed by a single echocardiographer. Patients 

Seventy-two patients (median age 36 years, 19 men) receiving cabergoline for hyperprolactinaemia, and 72 controls prospectively matched for age, sex and cardiovascular risk factors. Measurements 

Assessment of valvular mobility, regurgitation and morphology. Results 

Median cumulative dose exposure for cabergoline was 126 (58–258) mg, and patients had received cabergoline for 53 (26–96) months. The frequency of mild mitral regurgitation was identical (5/72, 7%) in patient and control groups. Mild aortic regurgitation was not significantly different between groups (4/72 [controls] vs 2/72 [patients], P = 0ยท681). There was only one case of tricuspid regurgitation, which was mild and observed in a cabergoline-treated patient. Nodular thickening of the right coronary cusp, noncoronary cusp or left coronary cusp of the aortic valve was observed at a similar frequency in both groups. There were no cases of extensive thickening of any valvular leaflet. Conclusion 

Our data demonstrates that there is no association between cabergoline treatment for hyperprolactinaemia and valvulopathy. This study therefore supports continued use of low-dose cabergoline for patients with hyperprolactinaemia.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Document Type: Research Article

Affiliations: 1: Department of Cardiology, Hammersmith Hospital, Imperial College, NHLI, London 2: Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Imperial College 3: Statistical Advisory Service, Imperial College, London, UK 4: Department of Diabetes and Endocrinology, Imperial College Healthcare NHS Trust

Publication date: September 1, 2010

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more